First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-09-06
DOI
https://doi.org/10.1200/jco.24.00576
Citations
15
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
8.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

Giuseppe Basile, D. Patanè, Matteo Bellone, Francesco De Cobelli et al.
15 citations
Journal of Clinical Oncology
Bladder and Urothelial Cancer Treatments
8.59
article

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

Giuseppe Basile, D. Patanè, Matteo Bellone, Francesco De Cobelli, Valentina Tateo, Benedetta Mattorre, Alberto Briganti, Dean C. Pavlick, Renzo Colombo, Roberta Lucianò, Giorgio Brembilla, Chiara Re, Antonio Cigliola, Daniele Raggi, Brigida Anna Maiorano, Andrea Necchi, Marco Moschini, Chiara Mercinelli, Laura Lucia Cogrossi, Maurizio Colecchia, Jeffrey S. Ross, Francesco Montorsi, Giovanni Luigi Pastorino
article en
15 citations

Abstract

To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.

Journal of Clinical OncologyVol. 42(35)
Vita-Salute San Raffaele University (IT), SUNY Upstate Medical University (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Ospedaliera Universitaria Pisana (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Foundation Medicine (United States)
Good health and well-being
Openalex Percentile: Top 2%
Bladder and Urothelial Cancer Treatments
8.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.